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Abstract
 
Both nuclear factor (NF)-
 
k
 
B–inducing kinase (NIK) and inhibitor of 
 
k
 
B (I
 
k
 
B) kinase (IKK)
have been implicated as essential components for NF-
 
k
 
B activation in response to many exter-
nal stimuli. However, the exact roles of NIK and IKK
 
a
 
 in cytokine signaling still remain con-
troversial. With the use of in vivo mouse models, rather than with enforced gene-expression
systems, we have investigated the role of NIK and IKK
 
a
 
 in signaling through the type I tumor
necrosis factor (TNF) receptor (TNFR-I) and the lymphotoxin 
 
b
 
 receptor (LT
 
b
 
R), a receptor
essential for lymphoid organogenesis. TNF stimulation induced similar levels of phosphoryla-
tion and degradation of I
 
k
 
B
 
a
 
 in embryonic fibroblasts from either wild-type or NIK-mutant
mice. In contrast, LT
 
b
 
R stimulation induced NF-
 
k
 
B activation in wild-type mice, but the re-
sponse was impaired in embryonic fibroblasts from NIK-mutant and IKK
 
a
 
-deficient mice.
Consistent with the essential role of IKK
 
a
 
 in LT
 
b
 
R signaling, we found that development of
Peyer’s patches was defective in IKK
 
a
 
-deficient mice. These results demonstrate that both NIK
and IKK
 
a
 
 are essential for the induction of NF-
 
k
 
B through LT
 
b
 
R, whereas the NIK–IKK
 
a
 
pathway is dispensable in TNFR-I signaling.
Key words: alymphoplasia • cytokine signaling • I
 
k
 
B • Akt kinase • Peyer’s patch
 
Introduction
 
The transcription factor nuclear factor (NF)-
 
k
 
B plays a piv-
otal role in the regulation of innate immunity, stress re-
sponses, inflammation, and the inhibition of apoptosis (1,
2). The activity of NF-
 
k
 
B is tightly regulated by cytokines
and other external stimuli. In most cell types, NF-
 
k
 
B is
present as a heterodimer comprising 50-kD (p50) and 65-
kD (p65) subunits and is sequestered in the cytoplasm by a
member of the inhibitor of 
 
k
 
B (I
 
k
 
B) family of inhibitory
proteins. NF-
 
k
 
B activation requires the degradation of I
 
k
 
B
proteins, and the mechanisms of I
 
k
 
B degradation and sub-
sequent NF-
 
k
 
B activation have been the subject of intense
investigation (3). Those studies have revealed two impor-
 
tant classes of kinase involved in this pathway: mitogen-
activated protein kinase kinase kinase (MAP3K) and its
downstream target, I
 
k
 
B kinase (IKK) (4, 5). NF-
 
k
 
B–induc-
ing kinase (NIK) is structurally related to MAP3K and has
 
been identified as a TNFR-associated factor (TRAF)2-
interacting protein (6). On the basis of the finding that ki-
nase-inactive mutants of NIK transfected into 293-EBNA
cells abolished NF-
 
k
 
B activation in response to TNF or by
cotransfection with type I TNF receptor (TNFR-I), NIK
was considered to be involved in an NF-
 
k
 
B–inducing sig-
naling cascade induced by TNF (6). Subsequently, NIK was
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demonstrated to phosphorylate IKK
 
a
 
 and IKK
 
b
 
, which di-
rectly associate with I
 
k
 
B
 
a
 
 and specifically phosphorylate it
on serines 32 and 36 (4, 5). These studies suggested that in-
teraction of NIK and IKK constitutes an essential step for
NF-
 
k
 
B activation. However, in vivo studies with mutant
mice have thrown some doubt on the essential roles of NIK
and IKK
 
a
 
 in NF-
 
k
 
B activation, at least as induced by TNF.
The alymphoplasia (
 
aly
 
) mouse is a natural strain with a mu-
tated NIK (7). Despite the NIK mutation, upregulation of
vascular cell adhesion molecule 1 (VCAM-1) after stimula-
tion with TNF was present in 
 
aly
 
 mouse embryonic fibro-
blasts (EFs) (8). It was also reported that 
 
aly
 
 mice exhibited
similar TNF-mediated endotoxin shock after generalized
LPS administration (7). These observations suggested that
NIK was not a critical element in the TNF signaling path-
way to NF-
 
k
 
B activation. The in vivo role of IKK in NF-
 
k
 
B activation was also examined using gene-targeted mice.
Although TNF-induced NF-
 
k
 
B activation was markedly
reduced in IKK
 
b
 
-deficient EFs (9, 10),
 
 
 
NF-
 
k
 
B activation
from IKK
 
a
 
-deficient EFs was normal (11, 12) or dimin-
ished but still present (13) after stimulation with TNF. Sur-
prisingly, mice deficient in IKK
 
a
 
 showed perinatal death
associated with limb and skin abnormalities, suggesting that
IKK
 
a
 
 plays an essential role in the regulation of gene ex-
pression required for the development of limb and skin
rather than for TNF signaling (11–13). Thus, the role of
NIK–IKK
 
a
 
 in NF-
 
k
 
B activation through TNFR signaling
requires further investigation.
The lymphotoxin 
 
b
 
 receptor (LT
 
b
 
R) has emerged as a
signaling system required for the development of lymphoid
organs (14, 15). Although LT
 
b
 
R has been shown to bind
TRAF2, -3, -4, and -5, but not TRAF6 (16, 17), and to
activate NF-
 
k
 
B after receptor ligation (18), the molecular
mechanisms by which LT
 
b
 
R exerts its biological activities
are still poorly understood. 
 
aly
 
 mice and LT ligand– or
LT
 
b
 
R-deficient mice share a unique phenotype, which in-
cludes the lack of LN and Peyer’s patches (PPs) and a dis-
turbed splenic architecture (7, 14, 15). Therefore, we spec-
ulated that NIK plays a role in LT
 
b
 
R signaling. This
hypothesis was supported by the demonstration that upreg-
ulation of VCAM-1 after stimulation with agonistic anti-
LT
 
b
 
R mAb was absent from 
 
aly
 
 mouse EFs (8).
Phenotypic analyses of mutant and gene-targeted mice,
as described above, have unveiled the essential roles of NIK
in lymphoid organogenesis and of IKK
 
a
 
 in limb and skin
development. However, the roles of NIK and IKK
 
a
 
 in cy-
tokine signaling still remain controversial. We have ap-
proached this question with the use of in vivo mouse mod-
els. Here, we show that NIK–IKK
 
a
 
 constitutes an essential
pathway for the induction of NF-
 
k
 
B through LT
 
b
 
R,
whereas this pathway is dispensable in TNFR-I signaling.
 
Materials and Methods
 
Mice. aly
 
/
 
1
 
, 
 
aly
 
/
 
aly
 
, and C57BL/6J mice were purchased
from CLEA Japan. The mice were maintained under pathogen-
free conditions and were handled in accordance with the Guide-
lines for Animal Experimentation of Tokushima University
 
School of Medicine. The experiments were initiated at 8–12 wk
of age. IKK
 
a
 
-deficient mice were generated by gene targeting as
described previously and maintained at Osaka University (11).
 
Use of EF to Assess Signaling through TNFR-I and LT
 
b
 
R.
 
EFs
were established as described previously (8, 11). EFs from 
 
aly
 
/
 
aly
 
mice, IKK
 
a
 
-deficient mice, and C57BL/6J wild-type mice were
cultured in DMEM (GIBCO BRL) supplemented with 10%
heat-inactivated FCS (GIBCO BRL), 2 mM 
 
l
 
-glutamine, 100
U/ml penicillin, and 100 
 
m
 
g/ml streptomycin at a density of 7 
 
3
105 cells per 60-mm culture dish. After incubation with control
mAb Ha4/8 (2 mg/ml), agonistic anti-LTbR mAb AC.H6 (2
mg/ml; reference 19), or recombinant human TNF (Genzyme,
Inc.), whole cell lysates were harvested from the dish with a lysis
buffer containing 1% NP-40 (Sigma-Aldrich) and subjected to
Western blot analysis as described previously (20). The following
Abs were used: rabbit antipeptide Ab directed against IkBa (cat.
no. sc-371; Santa Cruz Biotechnology), phospho-specific IkBa
(cat. no. 9241; New England Biolabs), and polyclonal rabbit Ab
against actin (Biomedical Technologies). For blockade of the
phosphatidylinositol-39-OH kinase (PI[3]K)–Akt pathway, EFs
were treated with 1 mM wortmannin (Calbiochem) for 30 min
before stimulation with TNF. For blockade of proteasome activ-
ity, EFs were treated with 100 mM N-acetyl-Leu-Leu-norleuci-
nal (ALLN; Nacalai Tesque) for 1 h.
Use of NF-kB Reporter Assay to Assess Signaling through TNFR-I
and LTbR. EFs cultured in a 35-mm culture dish (2 3 105
cells) were transfected with 2 mg of a reporter plasmid comprising
three repeats of the NF-kB site upstream of a minimal thymi-
dine kinase promoter and a luciferase gene in the pGL-2 vec-
tor (Promega), together with 2 mg of b-actin promoter–driven
b-galactosidase expression plasmid. Transfected cells were incu-
bated in the presence of recombinant human TNF (100 U/ml) or
agonistic anti-LTbR mAb AC.H6 for 8 h. After 24 h, the cells
were harvested in PBS and lysed in a luciferase lysis buffer, LC-b
(Piccagene). Luciferase assays were performed with a luminome-
ter (Lumat LB 9507; Berthold). Activity was normalized to
b-galactosidase activity, and data were expressed as the fold acti-
vation compared with stimulation by control anti-KLH hamster
mAb Ha4/8.
Assessment of LTbR Expression on EFs with Flow-cytometric Anal-
ysis. EFs were incubated with anti-LTbR mAb AF.H6 (19) or
control mAb Ha4/8. After washing twice with PBS, cells were
incubated with FITC-conjugated anti–hamster IgG mAb (clone
G94-56; PharMingen). Cells were analyzed with a FACSCali-
ber™ flow cytometer (Becton Dickinson) with CELLQuest™
software. Mouse mAb–producing hybridoma cells were used as
negative control.
Assessment of PP Formation with Whole-Mount Immunohistochem-
istry. Whole-mount immunohistochemistry for the detection of
PP was performed as described (21). In brief, 2% paraformalde-
hyde (pH 7.4)-fixed intestines from 18.5 days postcoitus (d.p.c.)
embryos were incubated with mAb against VCAM-1 (PharMin-
gen) and then with horseradish peroxidase (HRP)-conjugated
anti–rat Ig (Tago Immunologicals). Color development for
bound HRP was done with diaminobenzidine.
Assessment of Association between NIK and IKKa. Proteins
were expressed by transfecting expression constructs with the in-
dicated cDNAs into COS-7 cells. Extracts were prepared 30 h af-
ter transfection. Immunoprecipitation and Western blot analysis
was performed as described previously (20, 22). Full-sized, Flag-
tagged wild-type NIK (6), Flag-tagged aly-type NIK, and Myc-
tagged IKKa (22) were expressed in pCR3 vectors (Invitrogen);
aly-type NIK cDNA was generated by the introduction of an633 Matsushima et al. Brief Definitive Report
amino acid substitution (G860R) into the COOH-terminal re-
gion of human NIK (7) by site-directed mutagenesis. Anti-Flag
mAb (clone M2) and anti-Myc mAb (clone 9E10) were from
Sigma-Aldrich and Santa Cruz Biotechnology, respectively.
Results and Discussion
Retained TNFR-I Signaling in NIK-mutant EFs. NIK
was originally identified as a kinase that participates in
an NF-kB–inducing signaling cascade induced by TNF,
CD95, and IL-1 (6). To assess the impact of NIK mutation
in TNF responsiveness, we treated EFs from both wild-
type and aly mice with human TNF, which signals only
through mouse TNFR-I (23), and assessed NF-kB activa-
tion by Western blot analysis. Rapid IkBa degradation
concomitant with the appearance of phosphorylated IkBa
was observed with similar kinetics in EFs from both wild-
type and aly mice (Fig. 1 A). 30 min after stimulation with
TNF, IkBa started to recover similarly in both wild-type
and aly mice (Fig. 1 B). IkBb degradation in response to
TNF was also indistinguishable between wild-type and aly
mice (data not shown). We also tested TNF responsiveness
by titrating the TNF concentration between 0.1 and 100
U/ml. In this range, TNF sensitivity assessed by IkBa deg-
radation, and IkBa phosphorylation was indistinguishable
between wild-type and aly mice (Fig. 1 C). Using an NF-
kB–binding oligonucleotide probe in an electrophoretic
mobility shift assay (EMSA), we also observed a very simi-
lar level of NF-kB activation between wild-type and aly
mice in TNF-stimulated EFs or TNF-stimulated thy-
mocytes (data not shown). Furthermore, IL-1 and IL-6
production from TNF-stimulated EFs was indistinguishable
between wild-type and aly mice (data not shown). These
results demonstrate that NF-kB activation through TNFR-I
is not affected by the NIK mutation.
Recently, it was demonstrated that Akt serine–threonine
kinase is involved in the activation of NF-kB by TNF (24).
Although the results described above do not suggest a role
for NIK in TNFR-I signaling, it is possible that NIK plays
an important role in NF-kB activation in combination
with Akt. We therefore tested the combined effect of NIK
and Akt in the NF-kB–inducing pathway downstream of
the TNFR-I. IkBa degradation occurred 10 min after
TNF stimulation in wild-type EFs, even in the presence of
1 mM wortmannin, a sufficient concentration for blockade
of the PI(3)K–Akt pathway (references 24 and 25; Fig. 1
D). This suggests that Akt, the downstream target of
PI(3)K, by itself has no major role in NF-kB activation by
TNF. Additionally, no obvious effect of wortmannin on
IkBa degradation was observed in aly mouse EFs, indicat-
ing that NF-kB activation by TNF can occur even when
the functions of both NIK and Akt are inhibited. We failed
to observe phosphorylation of Akt in response to TNF
when we probed the same blot with phospho-specific anti-
Akt Ab in this experimental setting (data not shown).
These results suggest that neither NIK nor Akt is essential
for NF-kB activation by TNF and that other IKK kinase(s)
can substitute for NIK and Akt in NF-kB activation by
TNF, at least in EFs. Elucidation of the IKK kinase(s) that
activates IKK in response to TNF awaits further study.
Indispensable Role of NIK and IKKa in NF-kB Activation
through LTbR. We intended to evaluate the role of NIK
in TNFR-I and LTbR signaling with the use of in vivo
mouse models, rather than introducing enforced gene-
expression systems. To this end, we transfected EFs (which
express both TNFR-I and LTbR) only with a reporter
plasmid that has three repeats of the NF-kB site upstream
of a minimal thymidine kinase promoter and a luciferase
gene, and then stimulated the transfected EFs with TNF or
agonistic anti-LTbR mAb (AC.H6). EFs from both wild-
type and aly mice showed upregulation of luciferase activity
in response to human TNF (Fig. 2 A). The normal level of
TNF responsiveness in aly mice is consistent with the re-
sults shown above (Fig. 1). In contrast to TNF stimulation,
NF-kB activation in response to agonistic anti-LTbR mAb
was significantly reduced in aly mouse EFs, indicating that
NIK is involved in LTbR signaling (Fig. 2 A).
With the combination of EFs and agonistic anti-LTbR
mAb, signals for NF-kB activation assessed by EMSA were
not strong enough to evaluate the role of NIK in NF-kB
Figure 1. NF-kB activation in
response to TNF is retained in
EFs from NIK-mutant mice. EFs
from wild-type mice (WT) and
aly mice (aly) were stimulated
with TNF (100 U/ml), and cells
were harvested at the indicated
time points (A and B). IkBa deg-
radation (detected by anti-IkBa
Ab) and IkBa phosphorylation
(detected by phospho-specific
anti-IkBa Ab) was assessed by
Western blot analysis. Arrow in-
dicates phosphorylated IkBa (A).
EFs were stimulated with differ-
ent concentrations (Conc.) of
TNF ranging from 0.1 to 100
U/ml as indicated, and cells were
harvested 7 min after stimulation (C). EFs were stimulated with TNF (100 U/ml) with or without prior treatment with 1 mM wortmannin (D). The same
blot was probed with anti-actin Ab (bottom).634 Role of NIK and IKKa in TNF and Lymphotoxin Signaling
activation through the LTbR (our unpublished observa-
tion). Involvement of NIK in LTbR signaling was there-
fore examined by detection of IkBa phosphorylation in re-
sponse to agonistic anti-LTbR mAb. In wild-type EFs
stimulated with agonistic anti-LTbR mAb for 1 h, IkBa
phosphorylation was easily detected by Western blot analy-
sis (Fig. 2 B). In contrast, aly mouse EFs showed mini-
mal, if any, phosphorylated IkBa after LTbR stimulation.
Taken together, these results demonstrate that NIK is es-
sential for NF-kB activation in LTbR signaling, which ac-
counts for the abnormal lymphoid organogenesis in aly
mice.
We have previously demonstrated that EFs isolated from
IKKa-deficient mice can activate NF-kB in response to
TNF and IL-1, suggesting that IKKa is not essential for ei-
ther the TNF or IL-1 signaling pathways (11). The dis-
pensable role of IKKa in NF-kB activation through
TNFR-I was also confirmed by the detection of phosphor-
ylated IkBa in IKKa-deficient EFs after TNF stimulation
(Fig. 2 C). Because NIK is essential for LTbR signaling, as
demonstrated above, and NIK has been shown to phos-
phorylate IKKa (26), it is important to determine whether
IKKa is also essential for LTbR signaling. We therefore
treated EFs from IKKa-deficient mice with agonistic anti-
LTbR mAb and assessed NF-kB activation by the detec-
tion of phosphorylated IkBa. We found that IKKa-defi-
cient EFs showed no IkBa phosphorylation after LTbR
stimulation, suggesting that NIK–IKKa constitutes an im-
portant pathway in LTbR signaling (Fig. 2 B). LTbR ex-
pression assessed by flow-cytometric analysis with anti-
LTbR mAb (AF.H6) was similar among wild-type, aly,
and IKKa-deficient EFs (Fig. 2 D). The basal level of NF-
kB activation, assessed by the treatment of EFs with ALLN
alone, which blocks the degradation of phosphorylated
IkBa by proteasomes (3), was reduced in aly mice and re-
duced more profoundly in IKKa-deficient mice (Fig. 2 B).
The essential role of IKKa in LTbR signaling was ex-
amined by investigation of lymphoid organogenesis in
Figure 3. Lack of PP de-
velopment in IKKa-deficient
mice. Embryonic intestines iso-
lated from control littermates
(A) and IKKa-deficient mice
(B) were stained with anti–
VCAM-1 mAb. Arrows indicate
the sites of PPs. Original magni-
fication, 310.
Figure 2.  Impaired NF-kB
activation in response to LTbR
stimulation in NIK-mutant and
IKKa-deficient EFs. Wild-type
EFs and aly mouse EFs were
transfected with NF-kB re-
porter plasmids and stimulated
with TNF or agonistic anti-
LTbR mAb. 8 h later, NF-kB
activation was assessed by the
measurement of luciferase activi-
ties. Data were expressed as fold
activation compared with stimu-
lation by control mAb, and the re-
sults were plotted as the mean 6
SEM for a total of four indepen-
dent experiments. White and
black bars represent wild-type
EFs and aly mouse EFs, respec-
tively (A). EFs from wild-type,
aly, and IKKa-deficient mice
(IKKa2/2) were stimulated with
agonistic anti-LTbR mAb for
1 h, and IkBa phosphorylation
was assessed by Western blot
analysis (B, top). For the assessment of the basal level of NF-kB activation, EFs were treated with ALLN alone. Phosphorylated IkBa is indicated as P.
NS, nonspecific bands. The same blot was probed with anti-actin Ab (B, bottom). TNF stimulation induced IkBa phosphorylation in IKKa-deficient
EFs as in wild-type and aly EFs (C). LTbR expression assessed by flow-cytometric analysis with anti-LTbR mAb (D, thick line) was similar among wild-
type, aly, and IKKa-deficient EFs (D). Anti-KLH mAb Ha4/8 (D, thin line) and mouse hybridoma cells (top left) were used as negative control.635 Matsushima et al. Brief Definitive Report
IKKa-deficient mice. Because IKKa-deficient mice show
perinatal death associated with abnormal limb and skin
development, lymphoid organogenesis in IKKa-deficient
mice was assessed by the development of PP from 18.5
d.p.c. embryos. PP formation in control embryos (n 5 8)
was easily detected by whole-mount immunohistochemis-
try with mAb against VCAM-1 (Fig. 3 A); VCAM-11 cells
accumulate at the site of PP development starting from
15.5 d.p.c. and can be used as a stromal marker for PP for-
mation (21). In contrast, no PP formation was detected in
intestines isolated from IKKa-deficient embryos (n 5 7;
Fig. 3 B). A similar lack of VCAM-11 cell accumulation in
embryonic intestines has been demonstrated in aly mice
(21). This result shows that LTbR signaling is fundamen-
tally impaired in IKKa-deficient mice. Together, these
findings are important in providing clear evidence that
IKKa is involved in cytokine receptor signaling in vivo.
It is important to note that abnormal lymphoid organo-
genesis in IKKa-deficient mice is not due to defective re-
ceptor activator of NF-kB (RANK) signaling, because
mice deficient in RANK have PPs despite their lack of pe-
ripheral LNs (27); RANK activates NF-kB by recruiting
TRAF6, which has not been observed to associate with
LTbR (16, 17). It remains possible, however, that there
exist other undefined NIK–IKKa-activating receptor path-
ways involved in lymphoid organogenesis beyond LTbR.
The above data strongly suggest that NIK and IKKa to-
gether control LTbR signaling with a close mechanistic re-
lationship in their pathway. We have therefore reasoned
that impaired LTbR signaling in aly mice may be due to
defective interaction between mutated NIK and IKKa. To
investigate this, NIK and IKKa were coexpressed in COS-7
cells, and protein interactions were assessed by immuno-
precipitation. Association of wild-type NIK with IKKa
was easily detected (Fig. 4). In contrast, association of aly
type NIK, which corresponds to a G855R substitution in
mice, with IKKa was disrupted by the mutation, providing
further support for the role of NIK–IKKa as an essential
pathway for NF-kB activation in LTbR signaling. Despite
this finding, the possibility remains that aly mice might
have a different phenotype from NIK-null mutation mice.
It is unclear whether TRAFs mediate all of the signaling
activities of LTbR. In fact, mice deficient in TRAF2, -3,
or -5 show LN development (28, 29). In support of the
dispensable role of TRAFs in LTbR signaling, recent mu-
tational analyses of the cytoplasmic region of LTbR have
demonstrated a TRAF-independent mechanism of NF-kB
activation through LTbR (30). Consistent with this idea,
TRAF–NIK interaction in COS-7 cells as assessed by im-
munoprecipitation was not affected by the aly mutation
(our unpublished observation), although the aly mutation
resides in a putative TRAF-binding domain of NIK (31).
Elucidation of the molecular mechanisms by which NIK
becomes activated after LTbR stimulation will be critical
for understanding the biological nature of LTbR signaling.
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